India’s CDSCO warns pharma companies against promoting prescription weight-loss drugs like Semaglutide and Liraglutide to the public, urging ethical marketing and holistic obesity care.

The Drugs Controller General of India (DCGI) has issued strict warning against promotional activities, including “awareness campaigns," that functions as a surrogate advertisement for ...

Brands facing advertising restrictions have found ingenious ways to stay visible, from surrogate products to strategic partnerships. In this article, we explore how tobacco, alcohol, gambling, and ...